Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibiotics, Antineoplastic
  • Carcinoma, Renal Cell
  • Immunosuppression
  • Immunosuppressive Agents
  • Kidney Neoplasms
  • Sirolimus

abstract

  • Our findings, in addition to unlinking mechanisms of immunosuppression from that of tumor progression, suggest that rapamycin may be of value for the management of posttransplant malignancy.

publication date

  • May 27, 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 12042641

Additional Document Info

start page

  • 1565

end page

  • 72

volume

  • 73

number

  • 10